Cara Therapeutics Inc (NASDAQ:CARA) Expected to Post Earnings of -$0.67 Per Share

Equities analysts expect that Cara Therapeutics Inc (NASDAQ:CARA) will announce earnings per share of ($0.67) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Cara Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.64) and the lowest estimate coming in at ($0.75). Cara Therapeutics posted earnings per share of ($0.74) in the same quarter last year, which suggests a positive year-over-year growth rate of 9.5%. The company is scheduled to issue its next quarterly earnings report on Tuesday, November 3rd.

On average, analysts expect that Cara Therapeutics will report full year earnings of ($2.41) per share for the current year, with EPS estimates ranging from ($2.78) to ($1.89). For the next year, analysts anticipate that the business will post earnings of ($2.44) per share, with EPS estimates ranging from ($3.13) to ($1.16). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Cara Therapeutics.

Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.14. The business had revenue of $5.63 million during the quarter, compared to analyst estimates of $5.48 million. Cara Therapeutics had a negative return on equity of 65.97% and a negative net margin of 480.55%.

CARA has been the subject of several analyst reports. Cantor Fitzgerald boosted their target price on Cara Therapeutics from $34.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, May 19th. Needham & Company LLC restated a “buy” rating and set a $35.00 price objective on shares of Cara Therapeutics in a research report on Tuesday, August 11th. Zacks Investment Research lowered Cara Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 14th. Canaccord Genuity reissued a “buy” rating and issued a $30.00 price objective on shares of Cara Therapeutics in a research note on Tuesday, September 8th. Finally, BidaskClub lowered Cara Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 29th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $31.40.

In related news, CEO Derek T. Chalmers sold 3,201 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $16.00, for a total transaction of $51,216.00. Following the completion of the transaction, the chief executive officer now directly owns 953,220 shares of the company’s stock, valued at $15,251,520. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Derek T. Chalmers sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $17.11, for a total value of $85,550.00. Following the transaction, the chief executive officer now directly owns 961,421 shares of the company’s stock, valued at $16,449,913.31. The disclosure for this sale can be found here. Corporate insiders own 5.70% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Two Sigma Advisers LP boosted its position in Cara Therapeutics by 341.8% during the second quarter. Two Sigma Advisers LP now owns 99,400 shares of the biopharmaceutical company’s stock valued at $1,700,000 after purchasing an additional 76,900 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in Cara Therapeutics during the second quarter valued at approximately $324,000. Nuveen Asset Management LLC lifted its position in shares of Cara Therapeutics by 198.0% in the second quarter. Nuveen Asset Management LLC now owns 502,723 shares of the biopharmaceutical company’s stock valued at $8,596,000 after buying an additional 334,015 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Cara Therapeutics by 5.9% in the second quarter. Charles Schwab Investment Management Inc. now owns 279,590 shares of the biopharmaceutical company’s stock valued at $4,781,000 after buying an additional 15,637 shares during the last quarter. Finally, Engineers Gate Manager LP acquired a new stake in shares of Cara Therapeutics in the second quarter valued at approximately $204,000. 69.73% of the stock is owned by hedge funds and other institutional investors.

CARA traded down $0.14 on Wednesday, hitting $15.11. The company had a trading volume of 390,579 shares, compared to its average volume of 494,578. The company’s fifty day moving average price is $16.12 and its 200 day moving average price is $15.41. Cara Therapeutics has a 1-year low of $8.88 and a 1-year high of $26.67.

About Cara Therapeutics

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Further Reading: Street Name

Get a free copy of the Zacks research report on Cara Therapeutics (CARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.